Search results
Showing 6826 to 6840 of 8314 results
Moderately to severely active ulcerative colitis: adalimumab (ESNM6)
This evidence summary has been replaced by NICE technology appraisal guidance 329.
This evidence summary has been updated and replaced by NICE guideline NG28.
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
This guidance has been updated and replaced by NICE technology appraisal guidance 1103.
This guidance has been updated and replaced by NICE technology appraisal guidance 1054.
November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)
This guidance has been updated and replaced by NICE technology appraisal guidance 1018.
This guidance has been updated and replaced by NICE technology appraisal guidance 1043.
Dapagliflozin with insulin for treating type 1 diabetes (TA597)
In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.
PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)
This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.
September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.
September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)
This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.
Axonics sacral neuromodulation system for overactive bladder and faecal incontinence (MIB164)
This advice has been updated and replaced by NICE medical technologies guidance 50.
myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
This advice has been updated and replaced by NICE medical technologies guidance 68.
February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.